AXDX Accelerate Diagnostics, Inc: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $11.7M and net income of −$50.0M.
AXDX revenue and earnings
- Quarter ended Dec 31, 2024: revenue $2.82M, net income −$9.59M
- Quarter ended Sep 30, 2024: revenue $2.98M, net income −$14.6M
- Quarter ended Jun 30, 2024: revenue $2.99M, net income −$11.6M, EPS -0.50
- Quarter ended Mar 31, 2024: revenue $2.92M, net income −$14.2M, EPS -0.74
Recent AXDX insider trades
- Apr 4, 2025: Mertz Larry Michael sold 1,523 shares ($990)
- Apr 4, 2025: Phillips Jack sold 25,343 shares ($16.5K)
- Apr 1, 2025: Patience David sold 6,816 shares ($4.84K)
- Feb 26, 2025: Patience David sold 535 shares ($583)
5%+ owners
- Indaba Capital Management, L.P.: 9.9% (Schedule 13D/A, filed Feb 6, 2025)
- Armistice Capital, LLC: 7.5% (Schedule 13G/A, filed May 15, 2025)
Are insiders buying or selling AXDX?
No open-market insider buys or sells of Accelerate Diagnostics, Inc were reported in the last 12 months.
What was AXDX's revenue last quarter?
Accelerate Diagnostics, Inc reported revenue of $2.82M for the quarter ended December 31, 2024, with net income of −$9.59M.